MEDICAL IP vs MediView XR (2026)
Both turn a patient's scan into a three dimensional model of that patient, and they stop at different points. MEDICAL IP produces the segmentation and quantification, converting computed tomography and magnetic resonance into segmented anatomical models across one of the broadest multi jurisdiction regulatory portfolios in this index. MediView takes that kind of model into the procedure room, rendering the anatomy as a hologram and registering live ultrasound to it during image guided intervention, cleared for adjunctive use with the boundary written by a regulator. One produces the model, the other acts on it while a needle is moving. Neither publishes how segmentation or registration accuracy varies with body habitus, which is where an error in either would show up and where nobody is currently looking.
- Segmentation and quantification is the core capability, converting computed tomography and magnetic resonance into segmented anatomical models across a broad portfolio.
- One of the broadest multi jurisdiction regulatory portfolios in the index, built steadily over a decade rather than through a single clearance.
- The evidence record is among the strongest on this side of the index, with published validation behind the flagship products.
- The model is rendered into the procedure itself, projecting the patient's anatomy as a hologram and registering live ultrasound to it during image guided intervention.
- The regulatory position is the strongest on this side of the index, cleared for adjunctive use with the constraint written by a regulator rather than by marketing.
- Deployment is on premise in the procedure room by necessity, since the system registers to live imaging, which answers the data location question structurally.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. MEDICAL IP and MediView XR are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | MEDICAL IP | MediView XR |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2015 | 2017 |
| Headquarters | Seoul, South Korea | Cleveland, Ohio |
| Website | medicalip.com | mediview.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards MEDICAL IP its top capability grade on several axes, including AI Centrality, Clinical and Operational Evidence and FDA and Regulatory Status. Set against MediView XR, MEDICAL IP grades higher on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards MediView XR its top capability grade on FDA and Regulatory Status. Set against MEDICAL IP, MediView XR does not grade higher on any scored axis, though the two are level on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose MEDICAL IP or MediView XR?
The AI Health Index grades MEDICAL IP higher than MediView XR on every axis that separates them, several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. MediView XR does not grade higher on any scored axis.
Where do MEDICAL IP and MediView XR differ most?
The widest separation the AI Health Index records between MEDICAL IP and MediView XR is on AI Centrality, where MEDICAL IP grades A and MediView XR grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do MEDICAL IP and MediView XR grade the same?
The AI Health Index grades MEDICAL IP and MediView XR the same on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have MEDICAL IP and MediView XR not disclosed?
At the last review, at least one of MEDICAL IP and MediView XR published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Radiology & Imaging AI page.
Both derive anatomy from a patient's own imaging and neither publishes a subgroup or population performance analysis, which has a concrete form here: segmentation boundary accuracy and registration accuracy can both vary with body habitus, tissue characteristics and age, and an error in either propagates silently into whatever is built on it.
MEDICAL IP publishes no hosting, residency or data handling terms, and MediView publishes no health privacy statement or terms on whether procedural data leaves the hospital. Neither publishes pricing.